John Charin Somberg

John Charin Somberg's AcademicInfluence.com Rankings

John Charin Somberg

Philosophy

#8762

World Rank

#12202

Historical Rank

Logic

#5784

World Rank

#7218

Historical Rank

philosophy Degrees

Download Badge

Philosophy

John Charin Somberg's Degrees

Doctorate Medicine Stanford University

Why Is John Charin Somberg Influential?

(Suggest an Edit or Addition)

(See a Problem?)

John Charin Somberg's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

KCNE1 mutations cause Jervell and Lange-Nielsen syndrome (1997) (461)
Genetic polymorphisms. (2002) (296)
Neurocardiogenic Syncope (2009) (179)
Intravenous lidocaine versus intravenous amiodarone (in a new aqueous formulation) for incessant ventricular tachycardia. (2002) (174)
Biomarkers and surrogate endpoints. (1999) (119)
Bioavailability and Pharmacokinetics of Magnesium After Administration of Magnesium Salts to Humans (2001) (108)
Pharmacology and Pharmacokinetics of Amiodarone (1991) (99)
Relation of left ventricular mass and QT dispersion in patients with systematic hypertension. (1997) (95)
QT prolongation and the antiarrhythmic efficacy of amiodarone. (1986) (81)
Lack of a hypotensive effect with rapid administration of a new aqueous formulation of intravenous amiodarone. (2004) (76)
The Drug Development Process (1988) (70)
Multicenter trial of sotalol for suppression of frequent, complex ventricular arrhythmias: a double-blind, randomized, placebo-controlled evaluation of two doses. (1986) (68)
The cimetidine-lidocaine interaction. (1983) (62)
The arrhythmogenicity of antiarrhythmic agents. (1985) (60)
QT interval dispersion in healthy subjects and survivors of sudden cardiac death: circadian variation in a twenty-four-hour assessment. (1997) (59)
Localization of the neurally mediated arrhythmogenic properties of digitalis. (1979) (57)
Usefulness of QT dispersion as an electrocardiographically derived index. (2002) (53)
Comparative study of encainide and quinidine in the treatment of ventricular arrhythmias. (1986) (51)
The Effects of Chiral Isolates of Methadone on the Cardiac Potassium Channel IKr (2008) (50)
Influence of Electrolyte Abnormalities on Interlead Variability of Ventricular Repolarization Times in 12-Lead Electrocardiography (2001) (43)
Withdrawal of propranolol and myocardial infarction. (1973) (42)
Cibenzoline plasma concentration and antiarrhythmic effect (1984) (42)
Effect of intracoronary balloon inflation at percutaneous transluminal coronary angioplasty on QT dispersion. (1998) (41)
Myocardial infarction after propranolol withdrawal. (1974) (40)
Role of the nervous system in the genesis of cardiac rhythm disorders. (1976) (38)
Cardiovascular effects of nicotine: relation to deleterious effects of cigarette smoking. (1994) (36)
First-in-Man (FIM) clinical trials post-TeGenero: a review of the impact of the TeGenero trial on the design, conduct, and ethics of FIM trials. (2007) (35)
Prolonged repolarization: a historical perspective. (1985) (34)
Differential effect of glyburide (glibenclamide) and metformin on QT dispersion: a potential adenosine triphosphate sensitive K+ channel effect. (2002) (33)
The Art of Drug Synthesis (2009) (32)
The substrate and the trigger: the role of myocardial vulnerability in sudden cardiac death. (1987) (31)
Pharmacological Perspectives of Toxic Chemicals and Their Antidotes (2006) (31)
Pediatric drug development. (2003) (31)
The antiarrhythmic effects of d-sotalol. (1987) (31)
Alteration of the effects and distribution of ouabain by spinal cord transection in the cat. (1973) (31)
Proarrhythmia: definition, risk factors, causes, treatment, and controversies. (1994) (30)
Proarrhythmia of nonantiarrhythmic drugs. (1993) (29)
Prolongation of QT interval and antiarrhythmic action of bepridil. (1985) (29)
Antiarrhythmic effects of cibenzoline. (1985) (28)
QT Prolongation and Serum Sotalol Concentration Are Highly Correlated following Intravenous and Oral Sotalol (2010) (26)
The Clinical Pharmacology of Ethacrynic Acid (2009) (26)
Gender Differences in Cardiac Repolarization Following Intravenous Sotalol Administration (2012) (26)
Enhancement of Myocardial Vulnerability by Atrial Fibrillation (2004) (26)
Localization of the Neurally Mediated Coronary Vasoconstrictor Properties of Digitalis in the Cat (1981) (25)
Drug Delivery Systems (2004) (24)
Effect of angiotensin-converting enzyme therapy on QT interval dispersion. (1999) (24)
The Additive Effects of the Active Component of Grapefruit Juice (Naringenin) and Antiarrhythmic Drugs on HERG Inhibition (2007) (24)
Flecainide: long-term treatment using a reduced dosing schedule. (1985) (23)
Hemodynamic and surface electrocardiographic effects of a new aqueous formulation of intravenous amiodarone. (2002) (23)
Antiarrhythmic efficacy of ethmozine in patients with ventricular tachycardia as determined by programmed electrical stimulation. (1986) (22)
Developing a Safe Intravenous Sotalol Dosing Regimen (2010) (22)
Pacing termination of ventricular tachycardia: influence of antiarrhythmic-slowed ectopic rate. (1984) (21)
Differing sensitivities of Purkinje fibers and myocardium to inhibition of monovalent cation transport by digitalis. (1981) (20)
Evaluation of lorcainide in patients with symptomatic ventricular tachycardia. (1984) (20)
The influence of prostaglandins E1 and E2 on ouabain cardiotoxicity in the cat. (1977) (20)
Pharmacokinetics of Oral Cibenzoline in Arrhythmia Patients (1985) (20)
Chiral Cardiovascular Drugs: An Overview (2005) (19)
Adverse drug reaction reporting. (2000) (19)
Comparative Effects of Rapid Bolus Administration of Aqueous Amiodarone Versus 10-Minute Cordarone I.V. Infusion on Mean Arterial Blood Pressure in Conscious Dogs (2004) (18)
Neurally mediated augmentation of arrhythmogenic properties of highly polar cardiac glycosides. (1980) (18)
New directions in antiarrhythmic drug therapy. (1984) (17)
Martindale: The Complete Drug Reference (2005) (17)
The Effect of High Extracellular Potassium on IKr Inhibition by Anti-Arrhythmic Agents (2006) (16)
Assessment of cardiovascular and noncardiovascular medical device recalls. (2014) (16)
Neural basis for the genesis and control of digitalis arrhythmias. (1976) (15)
Supraventricular tachyarrhythmias: their evaluation and therapy. (1986) (15)
Pharmacology and Toxicology of a New Aqueous Formulation of Intravenous Amiodarone (Amio-Aqueous) Compared with Cordarone IV (2005) (15)
The pleiotropic effects of ethacrynic acid. (2009) (15)
The Influence of Extracellular Acidosis on the Effect of IKr Blockers (2005) (15)
The effect of bepridil, verapamil, and quinidine in the prevention of ventricular tachycardia induced by programmed electrical stimulation in the digitalized dog. (1984) (15)
Retrospective Study on the Analgesic Activity of a Topical (TT-CTAC) Cream in Patients With Diabetic Neuropathy and Other Chronic Pain Conditions (2015) (15)
Editorial: Deferred Consent: Issues In Clinical Research. (1995) (14)
Digitalis: Historical Development in Clinical Medicine (1985) (14)
Neural factors in digitalis toxicity: protective effect of C-1 spinal cord transection. (1978) (14)
Evaluation of the Effects of Different Energy Drinks and Coffee on Endothelial Function. (2015) (14)
A Mechanism for the Potential Proarrhythmic Effect of Acidosis, Bradycardia, and Hypokalemia on the Blockade of Human Ether-a-go-go-Related Gene (HERG) Channels (2005) (13)
Refractory ventricular tachycardia with flecainide. (1986) (13)
QT Dispersion: Still a Useful Measurement (2008) (13)
Evaluation of a 12-Lead Digital Holter System for 24-Hour QT Interval Assessment (2006) (13)
Bioterrorism and Infectious Agents (2006) (13)
American Journal of Therapeutics. (2002) (13)
Terazosin: pharmacokinetics and the effect of age and dose on the incidence of adverse events. (1991) (13)
Electrophysiology of Ethmozine (moricizine HCl) for ventricular tachycardia. (1987) (13)
Studies on the possible mechanisms of lidoflazine arrhythmogenicity. (1984) (12)
Sotalol versus Amiodarone in Treatment of Atrial Fibrillation. (2016) (12)
A Guide to Methods in the Biomedical Sciences (2006) (12)
Intravenous quinidine by intermittent bolus for electrophysiologic studies in patients with ventricular tachycardia. (1984) (12)
Retrospective Evaluation on the Analgesic Activities of 2 Compounded Topical Creams and Voltaren Gel in Chronic Noncancer Pain (2015) (12)
The management of acute heart failure and diuretic therapy. (2009) (12)
Hypercalcemia, arrhythmia, and mood stabilizers. (2000) (12)
Calcium channel blockers that prolong the QT interval. (1985) (12)
Efficacy of Intravenous and Oral Sotalol in Pharmacologic Conversion of Atrial Fibrillation: A Systematic Review and Meta-Analysis (2016) (12)
Antiarrhythmic drug efficacy at electrophysiology testing: predictive effectiveness of procainamide and flecainide. (1986) (12)
Prophylactic tocainide or lidocaine in acute myocardial infarction. (1986) (11)
Hypothyroidism Complicated by Angina Pectoris: Therapeutic Approaches (1992) (11)
How the Immune System Recognizes Self and Nonself (2009) (11)
Antiarrhythmic drug therapy. Recent advances and current status. (1985) (11)
Flecainide: a new antiarrhythmic agent. (1986) (11)
Blockade of tissue uptake of the antineoplastic agent, doxorubicin. (1978) (11)
Flecainide toxicity. (1984) (10)
Encainide: a new and potent antiarrhythmic. (1987) (10)
The clinical significance of polymorphic ventricular tachycardia provoked at electrophysiologic testing. (1985) (10)
To Begin Again (1994) (10)
The antiarrhythmic effects of quinidine and propranolol in the ouabain-intoxicated spinally transected cat. (1979) (10)
Digitalis: Neurally Mediated Arrhythmogenic and Coronary Vasoconstrictor Properties (1985) (10)
The Efficacy of Cibenzoline in Preventing PES Induction of Ventricular Tachycardia in the Dog (1984) (10)
The influence of spinal cord transection on the capacity of digitoxin to induce cardiotoxicity. (1974) (9)
Inhibitors of Protein Kinases and Protein Phosphatases (2005) (9)
The influence of heart rate on ouabain cardiotoxicity in cats with spinal cord transection. (1978) (9)
Extracellular Acidification and Hyperkalemia Induce Changes in HERG Inhibition by Ibutilide (2007) (9)
Editorial: Inertia in Clinical Research. (1996) (9)
Has the Promise Been Kept? (1992) (9)
Histamine antagonists as antiarrhythmic agents in ouabain cardiotoxicity in the cat. (1980) (9)
Retention of a Conditioned Avoidance Response after Metamorphosis in Mealworms (1970) (9)
The treatment of ventricular rhythm disturbances. (1986) (8)
Electrophysiologic evaluation of the antiarrhythmic effects of N-acetylprocainamide for ventricular tachycardia secondary to coronary artery disease. (1985) (8)
Model-Informed Development of Sotalol Loading and Dose Escalation Employing an Intravenous Infusion (2020) (8)
Ouabain cardiotoxicity, a reassessment of methodology. (1976) (7)
Cell Surface Receptors: A Short Course on Theory & Methods (2006) (7)
The Effect of Altered Renal Perfusion Pressure on Clearance of Digoxin (1980) (7)
Drug Development Costs (1987) (7)
Therapeutic approaches to the treatment of edema and ascites: the use of diuretics. (2009) (7)
Research in emergency care without consent: new proposed FDA rules (1996) (7)
Therapeutic approach to unstable angina: nitroglycerin, heparin, and combined therapy. (1993) (6)
Verapamil — Digitalis interaction: Effect on cardiac Purkinje fibers and myocardium (1982) (6)
Late stent thrombosis: problem or not? (2007) (6)
The Effect of Magnesium Sulfate on Action Potential Duration and Cardiac Arrhythmias (2005) (6)
Rapid Determination of Partition Coefficients Between n-Octanol/Water for Cardiovascular Therapies (2002) (6)
Long-term lorcainide therapy in patients with ventricular tachycardia. (1985) (6)
Effects of actodigin on the heart (1977) (6)
Hypoxia and the Circulation (2009) (6)
A choice, not an echo. (2000) (6)
THE EVOLVING DRUG DISCOVERY AND DEVELOPMENT PROCESS (1996) (6)
Lorcainide therapy for the high-risk patient post myocardial infarction. (1984) (5)
Renal elimination of digoxin: studies with tritiated digoxin and radioimmunoassay. (1981) (5)
Herbal-Drug Interactions and Adverse Effects (2004) (5)
False‐Positive Urine Protein Reaction with Cibenzoline, a New Antiarrhythmic Agent (1984) (5)
Chronic flecainide therapy selected by electrophysiology testing of intravenous flecainide. (1987) (5)
The influence of propranolol on ouabain uptake by the guinea pig heart. (1973) (5)
The effect of cimetidine administration on serum lidocaine levels in man (1982) (5)
Molecular Mimicry: Infection-inducing Autoimmune Disease (2006) (5)
Effect of quinidine on differing sensitivities of Purkinje fibers and myocardium to inhibition of monovalent cation transport by digitalis in dogs. (1983) (5)
Treating and Preventing Obesity (2004) (5)
Clinical Use of Class Ic Antiarrhythmic Drugs (1989) (5)
The quest for an aqueous amiodarone. (2003) (5)
Bioequivalence or Therapeutic Equivalence (1986) (5)
The Merck Index Fourteenth Edition (2007) (5)
Propafenone: a new antiarrhythmic agent. (1988) (5)
Clinical Therapeutic Conference (1991) (5)
Lorcainide therapy in a cardiac arrest population. (1986) (5)
A comparison of actodigin and ouabain in cats. (1977) (4)
Science, Politics and Hydroxychloroquine (2020) (4)
Letter: The action of propranolol in man and animals. (1976) (4)
Clinical trials registries. (2003) (4)
Safety and efficacy of flestolol, a new ultrashort-acting beta-adrenergic blocking agent, for supraventricular tachyarrhythmias. (1986) (4)
Ventricular rhythm disorders and sudden cardiac death. (1976) (4)
The report of the Institute of Medicine on drug safety. (2007) (4)
Refractoriness as a determinant of tachycardia inducibility in the right ventricle. (1987) (4)
The Calcium Channel Blockers. (1995) (4)
THE EFFECT OF DIPHENIDOL ON OUABAIN CARDIOTOXICITY IN THE CAT (1978) (4)
The effect of digoxin on the binding of adriamycin to cat heart muscle. (1977) (4)
PROSTAGLANDIN E1 ELECTROPHYSIOLOGICAL SAFETY IN PATIENTS WITH CONGESTIVE HEART FAILURE AND PERIPHERAL ARTERIAL OCCLUSIVE DISEASE (1997) (4)
The midodrine withdrawal. (2010) (4)
Antiarrhythmic action of bethanidine. (1984) (4)
Molecular Cancer Therapeutics: Strategies for Drug Discovery and Development (2004) (4)
Amiodarone Therapy Guided by Electrophysiologic Testing: An Update (1991) (4)
The pharmacologic treatment of heart failure. (2004) (3)
The Role of Electrophysiologic Testing in the Selection of Amiodarone Therapy (1989) (3)
Lithium, hypercalcemia, and arrhythmia. (1998) (3)
A federal solution a regulation for all. (2000) (3)
The influence of metiamide on ouabain cardiotoxicity. (1975) (3)
Biomedical Devices and Their Applications (2006) (3)
The Pace Quickens (1990) (3)
The Clinical Implications of First‐Pass Metabolism: Treatment Strategies for the 1990s (1993) (3)
Financing Technology’s Frontier (2004) (3)
The Impact of Comorbidities on Stroke Prophylaxis Strategies in Atrial Fibrillation Patients (2011) (3)
Van Nostrand??s Encyclopedia of Chemistry: Fifth Edition (2006) (3)
Who is teaching pharmacology. (2004) (3)
Reactions to Prescribed Drugs Kill Thousands Annually (1998) (3)
GENDER DIFFERENCES IN DRUG THERAPY (1996) (3)
Virtual Versus In-Person Learning as a Cardiologist During COVID-19 Pandemic (2020) (3)
The human microbiome and therapeutics. (2012) (3)
Device safety and effectiveness. (2010) (3)
67 PHARMACOLOGY AND TOXICOLOGY OF A NEW AQUEOUS FORMULATION OF INTRAVENOUS AMIODARONE (AMIO-AQUEOUS) IN COMPARISON TO CORDARONE IV (2005) (3)
A comparison of the in vivo and in vitro actions of ouabain to produce cardiac arrhythmia. (1974) (3)
A randomized comparative study of the electrophysiological and electrocardiographic effects of isradipine vs verapamil (1993) (3)
Comparison of noninvasive arrhythmia induction techniques with electrophysiologic studies and evaluation of lorcainide in patients with symptomatic ventricular tachycardia. (1984) (3)
Control of Cardiac Rhythm (1998) (3)
A challenge to America. (2001) (3)
The Evaluation of the Diuretic Action of Parenteral Formulations of Metolazone (2007) (3)
The Clinical Therapeutic Conference (1991) (3)
Evaluation of Dosing Interval and Optimum Dose of Cibenzoline (1987) (3)
Digitalis: 200 years in perspective. (1986) (3)
Localization of neurally mediated arrhythmogenic and coronary vasoconstrictor properties of digitalis. (1984) (3)
The Central Institutional Review Board (1999) (2)
The failing Ebola policy. (2014) (2)
Adverse Reactions of Amiodarone on the Thyroid (2016) (2)
Inhibition of Human Ether-A-Go-Go-Related Gene (hERG) Potassium Current by the Novel Sotalol Analogue, Soestalol. (2020) (2)
Who's Practicing Medicine (1990) (2)
Habituation of Mealworm Pupae, Tenebrio molitor, (1973) (2)
Lesson to be learned from the renal denervation trials. (2015) (2)
A Rapid Method to Evaluate Cardiac Repolarization Changes: The Effect of Two Coffee Strengths on the QT Interval (2015) (2)
Digitalis: Its Place in Therapy (1985) (2)
Patent foramen ovale closure devices: thoughts from the circulatory device advisory panel. (2007) (2)
Comparative Efficacy of Pirmenol and Procainamide in a Drug‐Resistant Population with Ventricular Tachycardia (1987) (2)
The Pharmaceutical Revolution: Drug Discovery and Development (2006) (2)
Risk Factors Not Addressed in Antihypertensive Therapy Based Solely on Blood Pressure Control (1993) (2)
The new year. (2015) (2)
Free exchange of ideas. (2003) (2)
New Approaches to Drug Selection and Serial Drug Testing (1984) (2)
Digoxin therapy for atrial fibrillation in the twenty-first century. (2014) (2)
Harrison??s Principles of Internal Medicine (2005) (2)
The Therapeutics of Hypertensive Emergency. (1996) (2)
Introduction to Drug Discovery and Development (2019) (2)
Cardiovascular drug development : protocol design and methodology (1999) (2)
Esmolol: A Novel Ultra‐short‐Acting Beta‐Blocking Agent (1986) (2)
Unfinished business in health care reform. (2011) (2)
Antiarrhythmic effects of indecainide in a drug-resistant population with ventricular tachycardia at programmed electrical stimulation. (1987) (2)
In Memoriam: Duncan Elliot Hutcheon June 1922–February 2010 (2010) (2)
Biomarker and surrogate endpoints. (2003) (2)
Ethmozine Toxicity: Fever of Unknown Origin (1986) (2)
Clinical therapeutic conference: congestive heart failure therapy. (2001) (2)
The heart vector, the regional information in the electrocardiogram, and QT dispersion: Reply (2002) (2)
The Dynamics of QT Dispersion (2009) (2)
The Dark Side of Implantable Cardioverter Defibrillator Therapy (2013) (2)
The Differential Antibacterial and Gastrointestinal Effects of Erythromycin and Its Chiral Isolates (2006) (2)
Mild heart failure: why the switch to ACE inhibitors? (1993) (2)
Introduction: Digitalis and Newer Inotropic Agents (1985) (1)
Topics in clinical pharmacology: cardiovascular and diabetes mellitus. (2010) (1)
The Spectrum of CAST I and II (1991) (1)
Class effects of pharmaceuticals and therapeutic interchangeability. (2001) (1)
The Drug Development Process and Clinical Practice (1990) (1)
Securing the US pharmaceutical supply. (2008) (1)
Reorganizing the flow of scientific information: is the age of electronic journalism here? (1999) (1)
Are we overregulated? (2001) (1)
International symposium on drug development. (1999) (1)
Are We on Course? (1992) (1)
The CAST Results (1990) (1)
Clinical Pharmacology Teaching (1987) (1)
Clinical Trials Methodology (2019) (1)
N-Acetylprocainamide's Antiarrhythmic Action in Patients with Ventricular Tachycardia (1986) (1)
New directions in antiarrhythmic drug therapy: the development of a promising new agent, lorcainide. (1984) (1)
A new therapeutic millennium [correction of millenium]. (2001) (1)
Van Gogh and Digitalis. (2020) (1)
The Food and Drug Administration Commissioner (1990) (1)
Atrial fibrillation and valve disease. (2002) (1)
Lessons From the Frontiers (1991) (1)
Successful heart failure therapy is effective antiarrhythmia therapy. (1996) (1)
Evaluating Serious Adverse Drug Reactions (2018) (1)
New FDA Initiatives (1993) (1)
Therapy for Late Post Infarction Ventricular Tachycardia (1985) (1)
Refractory heart failure. Comparison of time course of action of sublingual nitroglycerin and isosorbide dinitrate, oral or sublingual. (1978) (1)
Intravenous Sotalol for the Treatment of Ventricular Dysrhythmias in an Infant on Extracorporeal Membrane Oxygenation (2019) (1)
Risk assessment, drug approval, and liability. (2006) (1)
The Bretylium Saga: A Novel "Old Drug" for Cardiac Resuscitation. (2020) (1)
Is there an imperative for generic profiling to hasten the age of personalized medicine. (2012) (1)
A Practical Guide to Food and Drug Law and Regulation FDLI (2009) (1)
USE OF DUAL ANTIPLATELET VERSUS SINGLE ANTIPLATELET THERAPY FOR PREVENTION OF RECURRENT ISCHEMIC STROKE: META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (2015) (1)
Drug trial registries. (2004) (1)
Centralized Drug Development (1992) (1)
Proarrhythmia or Arrhythmogenicity. (1995) (1)
A case of herceptin cardiotoxicity. (2004) (1)
Nesiritide: the wrong controversy. (2005) (1)
Flecainide: Safety and Efficacy (2008) (1)
Lessons learned from the COX-2 advisory hearings. (2005) (1)
Antiarrhythmic drugs: making sense of the deluge. (1987) (1)
Supporting therapeutic innovation. (2009) (1)
Regulating Continuing Medical Education (1993) (1)
The Need for Stimulation. (2015) (1)
Guidelines for a new year. (2014) (1)
The Food and Drug Administration's paternalism. (2010) (1)
My Data, Your Data, Whose Data? (1990) (1)
The extrapolation of study results in the device approval process. (2009) (1)
Neurocardiogenic syncope with Addison's disease. (2000) (1)
Health care reform. (2009) (0)
APPROACHES TO INTRAVENOUS NITROGLYCERIN THERAPY (1996) (0)
New advances and new questions in cardiovascular therapeutics. (2009) (0)
21 EFFICACY OF LIDOCAINE AND A NEW AQUEOUS FORMULATION OF AMIODARONE IN THE TERMINATION OF SUSTAINED VENTRICULAR TACHYCARDIA. (2004) (0)
An Introduction to Human Genetics (2006) (0)
Medical isotope shortages. (2009) (0)
Is the device development process adequate. (2010) (0)
Guidelines or 10 commandments. (2012) (0)
A milestone in clinical pharmacology. (1996) (0)
On Stronger Footing (1992) (0)
Drug and device trials: should we ask more. (2011) (0)
Rheumatology & Immunology Therapy (2005) (0)
ACADEMIC JOURNALISM IN AMERICA (1997) (0)
To Board or Not (1992) (0)
The effect of opening coronary occlusion on QT dispersion (1998) (0)
Has the food and drug administration changed the drug approval process? (2011) (0)
The American College of Clinical Pharmacology in the Future (1989) (0)
PERSONAL RESPONSIBILITY OR GOVERNMENT FIAT (1999) (0)
About this journal. (2012) (0)
Harold Neu: In Memoriam (1998) (0)
The effect of quinidine and quinine on a potassium current (IKr) (2001) (0)
Does IV metolazone potentiate the diuretic action of IV furosemide (2001) (0)
Nonphysician Prescribing. (1996) (0)
Abstract 3703: The Effect of Naringenin and Antiarrhythmic Drugs on IKr Inhibition (2006) (0)
We Need More COVID Therapies (2023) (0)
DRUGS FOR ARRHYTHMIAS (1975) (0)
QT measurements following ace therapy (2003) (0)
Dismantling the FDA. (1995) (0)
Old drugs, new bottles, therapeutic advantage? (2002) (0)
The Scope of Clinical Pharmacology (1990) (0)
The Supremes got it right. (2013) (0)
82 INHIBITION OF THE HERG CHANNEL BY ASPIRIN: PH OR DIRECT EFFECT? (2007) (0)
The College in Change (1991) (0)
Sudden death in athletes. (2000) (0)
Abstract 17174: Revisiting the QT Correction Formulas: A Generalized Additive Models for Location, Scale, and Shape Approach (2020) (0)
Mandatory post marketing studies. (2007) (0)
The College and its Awards (1991) (0)
Rational therapeutics: dose titration and monotherapy in clinical practice. (1996) (0)
THE GOVERNMENTAL REVOLUTION (1995) (0)
THERAPEUTIC CASE REPORTS (1997) (0)
A Comparison of Tablets with Oral Suspension Formulation of Dipyridamole in Thallium Myocardial Imaging (1992) (0)
Current Opinions on the Trajectory of the Pharmaceutical Development (2019) (0)
THOMAS W. SMITH (1997) (0)
Welcome to the Annual Meeting (1993) (0)
Long term lorcainide therapy guided by electrophysiology studies. (1985) (0)
Drug Classification and Actions (1991) (0)
68 CHIRAL SEPARATION OF THE INOTROPIC AND CHRONOTROPIC ACTIONS OF DIGOXIN (2005) (0)
58 THE EFFECTS OF QUINIDINE AND ITS CHIRAL ISOLATES ON ERG-1SM POTASSIUM CURRENTS AND CORRELATION WITH GASTROINTESTINAL AUGMENTATION. (2006) (0)
The conflict of interest charade. (2013) (0)
Have we maxed out on new therapies. (2011) (0)
Drugs and the Liver (2010) (0)
B2 agonist inhalation increases QTc dispersion (1998) (0)
Clinical Pharmacology: Medicine or Pharmacology (1992) (0)
Arrhythmia therapy. (2002) (0)
From therapeutic nihilism to therapeutic success. (2011) (0)
Drugs From Discovery to Approval (2004) (0)
Therapeutics, drug pricing and innovation. (2003) (0)
14 COMPARATIVE EFFECTS OF RAPID BOLUS ADMINISTRATION OF AQUEOUS AMIODARONE VERSUS 10-MINUTE CORDARONE IV INFUSION ON MEAN ARTERIAL BLOOD PRESSURE IN CONSCIOUS DOGS (2005) (0)
Letter: Drugs for arrhythmias. (1975) (0)
Subject Index, Vol. 72, 1985 (1985) (0)
The influence of extracellular acidosis on the effect of Type III antiarrhythmic agents on the cardiac potassium channel (IKr) (2006) (0)
Should statins go OTC. (2004) (0)
Immunological Aspects of Neoplasm - The Role of the Thymus (2005) (0)
67 EVALUATION OF A 12-LEAD DIGITAL HOLTER SYSTEM FOR 24-HOUR Q-T INTERVAL ASSESSMENT. (2006) (0)
Pharmacotherapy: A Pathophysiologic Approach (2007) (0)
Amiodarone Challenges the Clinical Pharmacologist (1989) (0)
Making America more competitive: a paradigm shift in drug and device development. (2012) (0)
Drug Delivery System (1989) (0)
Proposed product labeling changes: does it really matter? (2001) (0)
Defining A Journal (1993) (0)
Managing heart failure patients with ACE inhibitors (1997) (0)
Stanley Gottlieb, MD, 1929-2007 (2007) (0)
Hypertension therapeutics in turmoil. (2003) (0)
Advances in cardiovascular pharmacology: protocol design and methodology--the US regulatory process. (1999) (0)
Stem-cell research. (2001) (0)
Inappropriate attack on device development. (2011) (0)
Are we facilitating therapeutic innovation? (2011) (0)
Therapeutic hangups. (2008) (0)
Biological Basis of Geriatric Oncology (2005) (0)
Drug Discovery and Development (2019) (0)
Heart rate variability / QT-dispersion 29 245 Altered RR Interval dynamics and vulnerability to life-threatening arrhythmias : fractal analysis (2004) (0)
807-5 Extracellular pH modifies drug blockade on the human ether-A-go-go related gene (HERG) channels (2004) (0)
What's gone wrong with clinical research. (2000) (0)
Non‐Approved Indications (1990) (0)
Biomarker Methods in Drug Discovery and Development (2009) (0)
Ic Antiarrhythmic Drugs (1989) (0)
Subject Index Vol. 106, 2006 (2006) (0)
Contents, Vol. 72, 1985 (1985) (0)
The Spectrum of CAST I and II (1991) (0)
Abstract 3596: The Effect of Chiral Isolates of Digoxin on Systemic Vascular Resistance (2006) (0)
THE FOURTH INTERNATIONAL SYMPOSIUM ON CARDIOVASCULAR DRUG DEVELOPMENT Developing Drugs for Ischemic Heart Disease (1995) (0)
Usefulness of electrophysiologic studies in predicting drug efficacy in patients receiving amiodarone. (1987) (0)
Corrected ethmozine dosage (1986) (0)
Sharing Regulatory Review Costs (1992) (0)
Symposium Introduction (1984) (0)
The Need for Randomized Clinical Trials (2007) (0)
CLINICAL THERAPEUTIC CONFERENCE: Therapeutic Considerations in Atrial Fibrillation Management (1996) (0)
A Symposium on Alpha Blockade (1993) (0)
OUS results, clinical studies and therapeutic innovation in America. (2014) (0)
The American College of Clinical Pharmacology: Challenges of the 90s (1990) (0)
Abstract 11416: The Effect of Deep Brain Stimulation on Autonomic Dysfunction in Parkinson Disease (2012) (0)
Physician specific prescribing information. (2006) (0)
Pharmacoeconomics: These Changing Times. (1994) (0)
Signing Off (2015) (0)
20 VENOUS IRRITATION WITH CORDARONE IV AND TWO DIFFERENT FORMULATIONS OF AQUEOUS AMIODARONE WHEN ADMINISTERED VIA PERIPHERAL VEINS. (2004) (0)
Smoking, Smoking Cessation, and Regulation. (1996) (0)
Let Us Do Not Forget Durability (2020) (0)
Do We Serve a Need (2021) (0)
Conflicts of Interest and “Nothing to Disclose” (2011) (0)
FDA Commissioner's Confirmation Hearings (1998) (0)
MISOPROSTOL AND EICOSANOIDS: A NEW AND EXCITING AREA OF THERAPEUTICS (1995) (0)
Therapies for COVID-19: A Disorganized Approach (2021) (0)
Big Science Little Science: Science in Controversy (1993) (0)
93 CHIRAL SEPARATION OF THE INOTROPIC AND CHRONOTROPIC ACTIONS OF DIGOXIN IN A CANINE MODEL. (2007) (0)
Abstract 11063: Evaluation of Different Energy Drinks and Coffee on Endothelial Function (2015) (0)
Ventricular Repolarization Spectra (2008) (0)
PRACTICE GUIDELINES, CONSENSUS CONFERENCES: THE PROS AND CONS (1995) (0)
The Educational Process (1991) (0)
The Importance of Cardiology Research (2020) (0)
This Past Year in Research (2021) (0)
Computerization in medicine. (2015) (0)
Habituation Of Mealworm Pupae, Tenebio-Molitor Coleoptera-Tenebrionidae (1973) (0)
Abstract 15024: Efficacy of Bretylium in Termination of Treatment Resistant Ventricular Tachycardia and Ventricular Fibrillation (2020) (0)
The Clinician Scientist (1998) (0)
A Milestone in Clinical Pharmacology (1991) (0)
Examination for Board Certification (1990) (0)
In Memoriam: Dr. James Black 1934–2010 (2010) (0)
The cholesterol hypothesis: questioned? (2008) (0)
Let Us Aggressively Confront the Coronavirus Pandemic (2020) (0)
The cart before the horse. (2013) (0)
THE FIFTH INTERNATIONAL SYMPOSIUM ON CARDIOVASCULAR DRUG DEVELOPMENT THE US REGULATORY PROCESS ADVANCES IN CARDIOVASCULAR PHARMACOLOGY: PROTOCOL DESIGN & METHODOLOGY (1995) (0)
The Journal's Development (1987) (0)
The stimulus package and medical therapeutics. (2009) (0)
Thrombolytic Therapy: A Drug Approvability Controversy (1987) (0)
The provisional approval step. (2005) (0)
Industry Under Siege (1993) (0)
Pharmaceutical Costs (1992) (0)
Intravenous nitroglycerin causing heparin resistance (1996) (0)
The QT Interval in Research (2021) (0)
Thoughts on Drug Development (1992) (0)
Off-label promotion. (2006) (0)
Heart Failure Research and Polypharmacy (2022) (0)
Evidence based or mechanism based therapeutics. (2009) (0)
The sins of ghostwriting. (2008) (0)
HOLD THAT PATENT (1997) (0)
The drug eluting stent challenge. (2008) (0)
Composite end points, black box warnings, and allegations of bias. (2010) (0)
Licensing to prescribe. (2008) (0)
FDA user fees and innovation. (2008) (0)
Guilt by association. (2007) (0)
Drug shortages and ensuring the U.S. supply of needed pharmaceuticals. (2012) (0)
Acquired Long QT Syndrome (2007) (0)
Contents Vol. 106, 2006 (2006) (0)
Antiarrhythmic Drug Therapy: A Continuously Evolving Field (1991) (0)
A perspective on the support of scientific research. (2013) (0)
The Direction of the ACCP (1993) (0)
The influence of liver injury on the distribution of digitoxin in the rat. (1974) (0)
Letter from Konstantinos P. Letsas et al. – Invited Editorial Comment (2006) (0)
The Cancer Myth. (1996) (0)
The Electronic Abstract System (2006) (0)
Physicians in Industry (1992) (0)
7 BLOCKADE OF HUMAN ETHER-A-GO-GO RELATED GENE (HERG) CHANNELS BY QUINIDINE. (2004) (0)
Editorial: Therapeutics, Clinical Phamacology, Molecular Pharmacology: Have We Lost Our Academic Way? (1994) (0)
10 THE DIFFERENTIAL EFFECTS OF ERYTHROMYCIN AND ITS CHIRAL ISOLATES ON GASTROINTESTINAL MOTILITY. (2004) (0)
Letter regarding articles by Kereiakes and Willerson, Mehran et al, and Kaplan et al, "mini-review: expert opinion". (2005) (0)
New Therapy update (1986) (0)
A comparison of IV adenosine vs. Oral dipyridamole in thallium imaging (1991) (0)
Drug Discovery: A History (2006) (0)
Venous irritation with Cordarone IV and two different formulations of Aqueous Amiodarone (2004) (0)
Genetic drug targeting. (2006) (0)
Branded Generics (1993) (0)
The hypertension peril and drug development. (2007) (0)
Digitoxin blockade of adriamycin cardiotoxicity in the rabbit (1982) (0)
Panel discussion (1995) (0)
Clinical Pharmacology of Therapeutic Proteins (2007) (0)
Clinical Therapeutic Conference: Sudden Death in a Young Athlete. (1995) (0)
Branded generics. (1993) (0)
The Regulatory Process (1986) (0)
Obesity therapeutics in the shadows: editorial. (2004) (0)
1154-97 Electrocardiogram morphology predictors of pharmacologic termination of ventricular tachycardia (2004) (0)
68 THE EFFECT OF ACIDOSIS AND HYPERKALEMIA ON THE IKr BLOCKING ACTION OF ANTIARRHYTHMIC DRUGS. (2006) (0)
Screening drugs for QT prolongation. (2007) (0)
Pharmaceutical companies and medical therapeutics education. (2006) (0)
Editorial: The Basis of Pharmaceutical Approval. (1994) (0)
Smoking Cessation Strategies. (1996) (0)
Drug Development and Patient Benefit (1991) (0)
Milestones for the College (1990) (0)
Clinical Pharmacology Programs (2002) (0)
Approach to chest pain: noncardiac and angina. Foreword. (2008) (0)
CHANGING THE REGULATORY PROCESS (1996) (0)
Clinical research oversight. (2002) (0)
69 THE EFFECT OF NARINGENIN (GRAPEFRUIT JUICE) AND ANTIARRHYTHMIC DRUGS ON IKr INHIBITION. (2006) (0)
The Pendulum Swings (1992) (0)
Do we need to accredit clinical research? (2001) (0)
Angiotensin-Neprilysin Combinations Marketing Poly or Therapeutic Optimization. (2015) (0)
The device development pinata. (2011) (0)
Let us regulate pharmaceuticals: here we go again. (2015) (0)
Off Label Indications. (1995) (0)
The Drug Development Conundrum (1991) (0)
Pediatric exclusivity and genericizing pharmaceuticals. (2001) (0)
An Invitation From the New Editors (1985) (0)
Abstract 12650: A Faster and Safe Way for Dose Escalation of Sotalol Therapy in Patients With Atrial Fibrillation or Flutter (2020) (0)
Is clinical research oversight adequate in the United States? (2000) (0)
Restricting physician prescribing. (2002) (0)
Clinical Therapeutic Conference (1992) (0)
Intellectual property. (2005) (0)
The hubris of science: defending the scientific process from political agendas. (2010) (0)
Abstract 11403: Medical Device Recalls in the U.S (2012) (0)
The Information Age and Therapeutics. (1995) (0)
Surrogate endpoints and drug approval. (2006) (0)
83 IS THE PH-INDUCED CHANGE IN IKR INHIBITION BY IBUTILIDE ARRHYTHMOGENIC? (2007) (0)
Clinical Therapeutic Conference: Thyroid Hormone Replacement in Hypothyroidism. (1995) (0)
2 VENOUS IRRITATION WITH CORDARONE IV AND TWO DIFFERENT FORMULATIONS OF AQUEOUS AMIODARONE WHEN ADMINISTERED VIA PERIPHERAL VEINS (2004) (0)
The Research Covenant (2003) (0)
An opportunity to distance the FDA from Washington politics. (2005) (0)
The politics of therapeutics. (2004) (0)
Is the evidence right in evidence-based practice? (2000) (0)
A Year of Participation (1991) (0)
Treatment of Psoriasis (2009) (0)
REVISITING ADVERSE DRUG REACTIONS (1996) (0)
SARS challenges therapeutics. (2003) (0)
Thoughts from the Editor (1992) (0)
Biologic problems. (2002) (0)
The generic conundrum. (2002) (0)
Can nitroglycerin convert effort-induced angina in men into silent myocardial ischemia? (1995) (0)
Therapeutics 2004. (2004) (0)
Proposed accelerated FDA approvals for special medical use. (2012) (0)
Publication Phobias (1993) (0)
Biologic generics. (2007) (0)
Contents Vol. 124, 2013 (2013) (0)
Courts, patents, litigation & patient care. (2014) (0)
Do We Serve a Need? (2021) (0)
What is a journal. (2004) (0)
Clinical trials and their surprises. (2014) (0)
The Promise of Chirality. (1995) (0)
Clinical Therapeutic Conference: Vancomycin Nephrotoxicity. (1994) (0)
THE YEAR IN REVIEW (1996) (0)
Medical judgment and therapeutics. (1999) (0)
The Anonymity of Drug Development (1986) (0)
What is New in Pharmacologic Therapy for Cardiac Resuscitation? (2020) (0)
Abstract 12649: A Faster and Safe Way to Initiate Sotalol Therapy for Patients With Atrial Fibrillation or Flutter (2020) (0)
1108 – STUDIES ON THE TOXICITY OF A CHARGED DIGITALIS DERIVATIVE (1978) (0)
52 THE INFLUENCE OF EXTRACELLULAR ACIDOSIS ON THE EFFECT OF ANTI-ARRHYTHMIC AGENTS ON THE CARDIAC POTASSIUM CHANNEL (IKr) (2005) (0)
The Need To Know (1985) (0)
Health care in turmoil. (2013) (0)
The Tension Builds (1993) (0)
A New Leadership (1990) (0)
Conflating the approval process and clinical research with pharmacoeconomic evaluation. (2013) (0)
Bioterrorism 2002. (2002) (0)
A NEW VIRUS AND THE ADEQUACY OF PUBLIC HEALTH METHODS (1995) (0)
The long acting antiarrhythmic properties ot a B-halo alkyi derivative of lidocaine (1990) (0)
Preclinical Development Handbook: Toxicology (2009) (0)
New Antibiotic Targets (2009) (0)
HISTAMINE AND ANTIHISTAMINES: CLINICAL PHARMACOLOGY FOR THE PRACTICING PHYSICIAN (1996) (0)
On the QT (2021) (0)
The new drug evaluation process: risk benefit ratio. (2005) (0)
Proceedings of the nineteenth annual symposium: advances in cardiovascular pharmacology: protocol design and methodology. the U.S. Regulatory Process. May 3, 4, 5, 2000, Washington, D.C. (2001) (0)
THE FDA and SOFTWARE (1996) (0)
Frontiers in Cardiology Research (2020) (0)
The cost of therapy. (2000) (0)
The drug safety review process. (2007) (0)
United States Patent ( 19 ) Ehrenpreis et al . 54 PARENTERAL SOLUTIONS CONTAINING AMODARONE IN ACETATE BUFFER SOLUTION (2017) (0)
International vs. hospital acquired infection. (2014) (0)
Acknowledgement to the Reviewers (2006) (0)
THE COMMERCIALIZATION OF RESEARCH (1996) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With John Charin Somberg?

John Charin Somberg is affiliated with the following schools: